OrganaBio, LLC has acquired substantially all operating assets of San Diego, California-based Excellos Inc., forming a coast-to-coast cell therapy contract development and manufacturing organization (CDMO). The deal creates a newly formed OrganaBio subsidiary, Excellos Labs, LLC, to oversee San Diego operations. The core Excellos team has been retained to ensure seamless continuity for existing customer programs. Financial terms were not disclosed.
The combined platform integrates OrganaBio’s East Coast strengths in adult leukapheresis (HemaCenter), birth tissue and cord blood sourcing (GaiaGift), PBMC isolation and cryopreservation with Excellos’ purpose-built San Diego facility featuring five ISO 7 cGMP cleanroom suites for autologous and allogeneic cell therapy manufacturing, cell isolation, expansion and fill/finish. OrganaBio also operates additional cell processing labs in San Francisco and Irvine, California.
The acquisition addresses supply chain risks for cell therapy developers by offering geographic redundancy, consistent quality standards and integrated services from starting materials through commercial manufacturing. The combined customer base includes many of the top 20 global pharmaceutical companies and a range of biotechnology developers focused on cancer and autoimmune indications. Full integration is expected over the next 12 months.
According to data captured in the LevinPro HC database, this transaction represents the 35th Life Sciences R&D acquisition of the year, as well as the 16th in the CDMO subsector. There were 84 Life Sciences R&D deals announced in 2025, including 42 CDMO deals. In 2024, there were 92 Life Sciences R&D and 30 CDMO transactions announced.
